16 results about "Protein overexpression" patented technology

This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.

The present invention relates to a fibroblast activation protein inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in the diagnosis or treatment of fibroblast activation protein overexpression diseases.

The application belongs to the technical field of genetic engineering, and particularly relates to application of AtPEN2 protein and / or its coding gene AtPEN2 in preventing cruciferous plant diseases. The application provides application of AtPEN2 protein and / or its coding gene AtPEN2 in preventing cruciferous plant diseases, and the amino acid sequence of the AtPEN2 protein is shown as SEQ ID NO. 1. The application takes Arabidopsis thaliana as a model plant to verify the prevention and treatment effect of overexpression of AtPEN2 protein on clubroot, and the results show that the AtPEN2 protein overexpression plant can improve the resistance to clubroot, indicating that the coding gene AtPEN2 of the AtPEN2 protein can be applied to molecular breeding of clubroot, and provides a new gene resource for molecular breeding of cruciferous crops.

The invention relates to a fibroblast activating protein inhibitor, a pharmaceutical composition containing the compound and application of the fibroblast activating protein inhibitor in diagnosis or treatment of fibroblast activating protein overexpression diseases.

The application discloses TaSMAX1 protein and application of a coding gene thereof in promoting salt tolerance of wheat seedlings, and belongs to the technical field of biotechnology, and particularly relates to application of TaSMAX1 protein and a coding gene thereof in promoting salt tolerance of wheat seedlings, wherein the protein is SEQ ID NO:2, and the coding gene is 58-3123 of SEQ ID NO:1. Experiments prove that, compared with a receptor plant Fielder, a survival rate of a TaSMAX1 protein overexpression strain under salt treatment is significantly improved, it is proved that overexpression of the TaSMAX1 protein can enhance salt tolerance of the wheat seedlings in the seedling stage, gene resources are provided for breeding of high-yield and high-quality wheat varieties, and the application has a wide application prospect.

This invention discloses the application of WWP1 as a targeted biomarker for estrogen receptor-positive breast cancer. By detecting WWP1 gene amplification or protein overexpression, this invention can be used to assess ER. + Important biomarkers for prognosis and predicting response to CDK4 / 6 inhibitor therapy in breast cancer patients. This invention further provides a combination of WWP1 inhibitors and CDK4 / 6 inhibitors that exhibits potent synergistic antitumor effects both in vitro and in vivo, effectively overcoming drug resistance and improving the tumor immune microenvironment. Particularly in ER⁺ breast cancer patients, the combination therapy significantly improves treatment efficacy, providing a novel treatment strategy. This invention provides a novel ER⁺... + An integrated approach to breast cancer prognosis assessment and treatment has significant clinical application value.

The invention discloses a rice LPA1 gene and application of the rice LPA1 gene in regulation and control of phosphorus nutrient accumulation of plants. The gene sequence is shown as a sequence table SEQ ID No: 1, and the protein sequence is shown as a sequence table SEQ ID No: 2. It is identified for the first time that LPA1 gene expression can obviously regulate phosphorus nutrient accumulation, rice LPA1 protein mutation enables phosphorus nutrient accumulation to be reduced, and rice LPA1 protein overexpression enables phosphorus nutrient accumulation to be enhanced. The protein and the coding gene thereof have important theoretical and practical significance for improving phosphorus nutrient accumulation of plants and crop yield, can play an important role in genetic breeding of crops, and have wide application prospects.

The present disclosure provides methods for treating MET-associated non-small cell lung cancer or inhibiting the growth of MET-associated non-small cell lung cancer comprising selecting a subject having cancer and administering a therapeutically effective amount of a MET x MET bispecific antibody wherein each binding arm of the bispecific antibody interacts with a different MET epitope. In certain embodiments, the cancer contains an MET alteration, such as an exon 14 alteration in DNA or a deletion that results in exon 14 skipping, MET gene amplification, or MET protein overexpression.

The present invention relates to a novel antibody binding to human CCL7 (C-C motif chemokine ligand 7). As an antibody with the effect of inhibiting chemotaxis of monocytes, the antibody of the present invention can be developed as a therapeutic agent for diseases associated with CCL7 protein overexpression and can also be used in a diagnostic system targeting the CCL7 protein.

The application discloses ZmRLR1 application of a gene and a coded protein in regulating corn root development. ZmRLR1 The nucleotide sequence of the gene is shown in the sequence table SEQ ID No: 1, and the protein sequence is shown in the sequence table SEQ ID No: 2. The number of lateral root primordia, the total length of lateral roots and the total lateral root density of the seedling stage of the ZmRLR1 protein overexpression transgenic plant are significantly increased, the number and size of the root system of the fifth layer of crown roots at the mature stage are significantly increased, and the weight of the rhizosphere soil is increased.

The invention relates to a construction method and application of an ANGPTL3 overexpression laying hen fatty liver hemorrhagic syndrome model, and the construction method comprises the following steps: (1) respectively integrating a transposon element carrying a chicken ANGPTL3 coding gene and a transposase gene into an adenovirus vector, and obtaining a recombinant adenovirus by using a virus packaging system; (2) punching the chick embryos developed for 4 days (E4) by adopting an equatorial plane windowing method; (3) introducing the recombinant adenovirus into an E4 chick embryo body in a microinjection manner; and (4) hatching to laying hens to prepare the laying hen fatty liver hemorrhagic syndrome model. The animal disease model is constructed on poultry through protein overexpression for the first time, and the laying hen fatty liver hemorrhagic syndrome model does not need to be fed with high-fat feed and has the advantages of being accurate in animal model construction, remarkable in fatty liver characterization and high in efficiency. The method has a great application value in research on the fatty liver hemorrhagic syndrome of laying hens and drug development and screening of poultry.

The application discloses application of OsHTT6 protein in regulating high-temperature stress tolerance and yield of rice. The application finds that inhibiting expression of the OsHTT6 protein can improve the high-temperature stress tolerance of rice, improve the survival rate of rice seedlings after suffering high-temperature stress, and improve the single-plant yield of rice by constructing an OsHTT6 protein function loss mutant rice strain and an OsHTT6 protein overexpression transgenic rice strain; and overexpression of the OsHTT6 protein can reduce the high-temperature stress tolerance of rice, and reduce the single-plant yield of rice. That is, the high-temperature stress tolerance of rice and the yield of rice can be regulated by regulating expression of the OsHTT6 protein; a reagent capable of inhibiting expression of the OsHTT6 protein can be used to improve the high-temperature stress tolerance and yield of rice, or a heat-resistant and high-yield rice plant can be constructed. The application is favorable for cultivation of heat-resistant and high-yield rice varieties.

The invention relates to a sulfonyl compound and a pharmaceutical composition and application thereof, the sulfonyl compound comprises a compound shown in a formula I, the sulfonyl compound is competitively combined with KAT6A / KAT6B in a binding pocket of KAT6A / KAT6B substrate acetyl coenzyme, the acetyl coenzyme is inhibited from being combined with KAT6A / KAT6B to catalyze histone related sites, gene expression inducing cancer cell growth is prevented, and the cancer cell growth is inhibited. Further, the KAT6A / KAT6B gene can be used for treating related tumor diseases caused by KAT6A / KAT6B gene amplification or KAT6A / KAT6B protein overexpression.

The invention provides a compound shown in a formula (I) or pharmaceutically acceptable salt thereof, and the compound or the pharmaceutically acceptable salt thereof can be used as a KAT6 inhibitor for treating cancers, and is particularly used for treating tumor diseases related to KAT6A / KAT6B gene amplification or KAT6A / KAT6B protein overexpression.

The invention discloses an application of an overexpression agent of a TRIM7 gene and / or a TRIM protein in preparation of an anti-rabies drug. According to the invention, by measuring the expression level of rabies virus structural genes / proteins in cells infected with rabies virus after overexpression of TRIM7 and healthy cells, it is determined that the overexpression agent of TRIM7 gene and / or TRIM protein can be used for resisting rabies, inhibiting the growth of rabies and / or reducing the titer of rabies virus, thereby reducing the proliferation of rabies virus. Therefore, the composition using the product containing the over-expressed TRIM7 gene and / or TRIM7 protein can effectively prevent and / or treat rabies.